caa a22 4500 47707247X CHVBK 20180405111430.0 cr unu---uuuuu 170330e19960901xx s 000 0 eng 10.1007/BF00051114 doi (NATIONALLICENCE)springer-10.1007/BF00051114 Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: Results of SHIPS (SHIga Pravastatin Study) [Elektronische Daten] [Yasuyuki Nakamura, Osamu Yamaoka, Kazunori Uchida, Naoki Morigami, Yoshihisa Sugimoto, Tamotsu Fujita, Teruro Inoue, Toshikazu Fuchi, Masataka Hachisuka, Hirotsugu Ueshima, Harumi Shimakawa, Masahiko Kinoshita] Summary: We conducted a multicenter prospective, randomized, double-blind, placebo-controlled trial to test whether pravastatin, a hydroxymethyl glutaryl coenzyme A reductase inhibitor, can decrease restenosis after percutaneous transluminal coronary angioplasty (PTCA). Pravastatin 10 mg twice daily was begun at least 10 days prior to elective PTCA in patients with total cholesterol less than 280 mg/dl. The end-point was a between-group comparison of the frequency of restenosis defined as a more than 50% loss of the initial gain in diameter stenosis at the PTCA site at 3 months during follow-up by automated quantitative coronary arteriography. Of 207 patients randomly assigned to study groups, 139 patients underwent PTCA; 133 procedures were successful, and 124 patients underwent follow-up angiography at 3 months, and 179 lesions (85 pravastatin, 94 placebo) in 124 patients (62 pravastatin, 62 placebo) were analyzed. The two groups were comparable for baseline characteristics. Total cholesterol decreased by 19.6% in the pravastatin group (p<0.001) but not in the placebo group. Although the restenosis rate was not different in the two groups (29.4% in pravastatin vs. 39.4% in placebo, p=0.215) as a whole, it was reduced to about one fifth (8.8%) in the pravastatin group compared with 14.8% in the placebo group (p=0.0011) when the comparison was restricted to high grade lesions (≥75% diameter stenosis, 34 lesions in pravastatin, 29 lesions in placebo). Pravastatin thus reduces restenosis after PTCA of high grade lesions. Kluwer Academic Publishers, 1996 restenosis nationallicence PTCA nationallicence pravastatin nationallicence HMG-CoA reductase inhibitor nationallicence Nakamura Yasuyuki Shiga University of Medical Science, Seta, Otsu, Japan aut Yamaoka Osamu Shiga University of Medical Science, Seta, Otsu, Japan aut Uchida Kazunori Shiga University of Medical Science, Seta, Otsu, Japan aut Morigami Naoki Shiga University of Medical Science, Seta, Otsu, Japan aut Sugimoto Yoshihisa Shiga University of Medical Science, Seta, Otsu, Japan aut Fujita Tamotsu Shiga University of Medical Science, Seta, Otsu, Japan aut Inoue Teruro Shiga University of Medical Science, Seta, Otsu, Japan aut Fuchi Toshikazu Shiga University of Medical Science, Seta, Otsu, Japan aut Hachisuka Masataka Shiga University of Medical Science, Seta, Otsu, Japan aut Ueshima Hirotsugu Shiga University of Medical Science, Seta, Otsu, Japan aut Shimakawa Harumi Shiga University of Medical Science, Seta, Otsu, Japan aut Kinoshita Masahiko Shiga University of Medical Science, Seta, Otsu, Japan aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/4(1996-09-01), 475-483 0920-3206 10:4<475 1996 10 10557 https://doi.org/10.1007/BF00051114 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00051114 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nakamura Yasuyuki Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Yamaoka Osamu Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Uchida Kazunori Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Morigami Naoki Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Sugimoto Yoshihisa Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Fujita Tamotsu Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Inoue Teruro Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Fuchi Toshikazu Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Hachisuka Masataka Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Ueshima Hirotsugu Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Shimakawa Harumi Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 700 1- Kinoshita Masahiko Shiga University of Medical Science, Seta, Otsu, Japan aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/4(1996-09-01), 475-483 0920-3206 10:4<475 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer